ISSN 2330-717X

French Nasal Vaccine Project Against COVID-19 Blocks All Transmission Of The Virus


Since June 2020, the BioMAP research team of the INRAE-Université de Tours Infectiology and Public Health (ISP) joint research unit, a member of the Carnot Institute’s France Futur Elevage network, has been working on the development of a nasal vaccine against the SARS-CoV-2 virus, with the support of several teams from universities, academia and INRAE.


Pre-clinical tests had demonstrated the efficacy of the vaccine candidate after two nasal immunisations delivered three weeks apart, both in terms of the immune response and early neutralisation of the original virus and its variants, greatly decreasing the risk of contamination by a vaccinated individual[1]. The results of this non-adjuvanted protein vaccine were confirmed at the end of 2021 by new pre-clinical trials on rodents validating its effectiveness against the Delta variant. The vaccine, consisting of the spike protein and non-mutated viral proteins, would therefore protect against the currently circulating strain of SARS-CoV2 despite multiple mutations.

The support of the ANRS | Maladies infectieuses émergentes[2] on this vaccine candidate will allow the consolidation of the design as well as monitoring all the phases to be carried out until market launch.

Decisive next steps: fund-raising, production of vaccine batches and first clinical trials

Founded by Isabelle Dimier-Poisson from the UMR ISP and head of the BioMAP research team at the origin of the project and Patrick Barillot, former development director at Recipharm, the start-up LoValTech (for Loire Valley Technology) has held an exclusive licence to exploit the vaccine candidate since its creation in January 2022, granted jointly by the Université de Tours and INRAE. Mathieu Epardaud (INRAE researcher) and Nicolas Aubrey (associate professor at the Université de Tours), both members of BioMAP, are also part of the adventure as partners and will be scientific consultants for the startup. The ANR and the Centre-Val-de-Loire region provided an initial funding of €500,000 for scientific development. The Ministry of Higher Education, Research and Innovation allocated a further €1.5 million and the ANRS | Maladies infectieuses émergentes 0.9 million, for a total of €2.4 million, to the Université de Tours in order to carry out the production of the vaccine proteins in a GMP (Good Manufacturing Practice) environment, essential for clinical trials. From the first quarter of 2022, the challenge will be to produce this biomedicine through the Toulouse-based company GTP Bioways and to launch the production of clinical batches for clinical trials in the second quarter.

At the same time, the specific instillation systems – a novel design – of this vaccine in the nose are the subject of collaborative exchanges with two specialised companies, Resyca and Aptar Pharma.

Lastly, discussions on the design of the clinical trials and the drafting of the phase I protocol will be initiated over the next few weeks with the support and expertise of the ANRS | Maladies infectieuses émergentes, sponsor of these future clinical trials. The Clinical Investigation Centre of the CHRU (the Tours Regional University Hospital, a joint structure of the University Hospital, the University and Inserm) has already committed to conducting these clinical trials with other investigators.    


Non-invasive and requiring minimal logistics, this vaccination system will allow for a wider distribution:

  • to countries with a satisfactory vaccination coverage rate as a booster vaccination in order to strengthen the immune response – particularly the mucosal one – to protect the vaccinated population from symptomatic forms of the disease and, above all, to avoid transmission of the virus.
  • to countries where the population is not vaccinated as a first dose.

[1] This vaccine was first tested in vivo in a pre-clinical murine model. Two nasal applications, three weeks apart, induced a strong humoral immune response – in particular of the mucosal immunoglobulin A (IgA) with a neutralising and polyspecific activity, i.e. effective against the different variants of SARS-CoV-2 – along with a strong cellular response in the nasal cavities and lungs.

[2] Created on 1 January 2021, the ANRS/ Maladies infectieuses émergentes is the new autonomous agency of INSERM, created by the merger of the REACTing consortium and the National Agency for AIDS Research (ANRS) under the joint impetus of its two supervisory ministries, the Ministry of Higher Education, Research and Innovation and the Ministry for Solidarity and Health.

Leave a Reply

Your email address will not be published.